Has the CONVINCE trial convinced the nephrology and dialysis community?
Julien Moury,Gauthier Nendumba,Arnaud Robert,Benedicte Hauquiert,Ovidiu Vornicu,Sydney Blackman,Emily Perriens,Nathan De Lissnyder,Andriy Shchukin,Farah El Yaakoubi,Clara Saad,Cyril Schmit,Anne-Sophie Dincq,Patrick Evrard,Pierre Bulpa,Isabelle Michaux,Patrick M. Honore
DOI: https://doi.org/10.21037/atm-24-50
IF: 3.616
2024-10-19
Annals of Translational Medicine
Abstract:Julien Moury 1 , Gauthier Nendumba 1 , Arnaud Robert 1 , Benedicte Hauquiert 1 , Ovidiu Vornicu 1,2 , Sydney Blackman 3 , Emily Perriens 4 , Nathan De Lissnyder 4 , Andriy Shchukin 4 , Farah El Yaakoubi 4 , Clara Saad 4 , Cyril Schmit 4 , Anne-Sophie Dincq 1,2 , Patrick Evrard 1 , Pierre Bulpa 1 , Isabelle Michaux 1 , Patrick M. Honore 1 1 ICU, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium; 2 ICU and Anesthesiology Departments, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium; 3 Department of gynecology, Centre Hospitalier interregional Edith Cavell (Chirec Hospital), Brussels, Belgium; 4 Faculty of Medicine, ULB University, Brussels, Belgium Comment on: Blankestijn PJ, Vernooij RWM, Hockham C, et al . Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure. N Engl J Med 2023;389:700-9. Keywords: High-flux hemodialysis (HFH); high-dose hemodiafiltration; improved prognosis; applicability; chronic dialysis patients Submitted Mar 03, 2024. Accepted for publication Aug 08, 2024. Published online Sep 05, 2024. doi: 10.21037/atm-24-50 The CONVINCE trial, conducted during the summer of 2023, represents a pivotal moment in nephrology, addressing the longstanding question of whether high-volume hemodiafiltration (HVHDF) can significantly reduce mortality in patients with kidney failure (KF). This pragmatic, multinational, randomized controlled trial (RCT) involved 1,360 patients who had been undergoing high-flux hemodialysis (HFH) for at least three months (1). Participants were randomly assigned to either continue with conventional HFH or switch to HVHDF, with a convective volume target of at least 23 liters per session, exclusively in post-dilution mode. The primary outcome of interest was mortality from any cause, assessed over median follow-up period of 30 months. Throughout the trial, the HVHDF group achieved a mean convection volume of 25.3 liters per session in post-dilution mode. The results indicated a mortality rate of 17.3% in the HVHDF group compared to 21.9% in the HFH group, with a hazard ratio of 0.77 [95% confidence interval (CI): 0.65 to 0.93] (1). Additionally, the target convective volume of at least 23±1 liters per session was met in 92% of the HVHDF sessions delivered (1). Aim and rationale behind the CONVINCE trial: evaluating high-dose hemodiafiltration: what trigger the authors to design the CONVINCE trial? The primary aim of the CONVINCE trial was to assess whether HVHDF could reduce overall mortality in patients with KF who had been undergoing HFH for at least three months (1). The goal was to achieve a high convective dose of 7.75 liters per hour for 4 hours in post-dilution to eliminate uremic toxins, cytokines, and other physiological waste products (2,3). Previous research, including a pilot RCT by Honore et al. in 2000, suggested potential benefits of high convective doses in improving hemodynamic stability and reducing mortality, particularly in acute settings. This study aimed to investigate the potential improvement of hemodynamic status in patients with refractory septic shock through the removal of cytokines (though not measured) (4). It used pulse high-volume hemofiltration (P-HVHF) with a convection dose of 9 liters per hour over four hours in post-dilution, showing acute hemodynamic improvement in 20 patients with septic shock (4). However, due to its small sample size and varied methodologies, the results were inconclusive results. The ESHOL trial conducted by Maduell et al. in 2013 provided the first robust evidence that high convective doses could improve all-cause mortality compared to standard HFH (5). This trial demonstrated that patients receiving intermediate tertile convection volumes (23.1–25.4 L) and upper tertile convection volumes (>25.4 L) experienced lower mortality rates than those undergoing hemodialysis. Thus, the ESHOL trial was the first to show that achieving a convective volume of more than 18 liters per session with HVHDF is associated with a reduction in all-cause mortality (5). Despite this, subsequent RCTs on continuous HVHF, including an important meta-analysis, reported negative results in terms of mortality, likely because they did not achieve such high convection volumes exclusively in post-dilution (4,6,7). Motivated by these findings, the CONVINCE trial aimed to definitively evaluate the benefits of HVHDF by achieving a convection volume of over 23 liters per session. The trial found that patients receiving HVHDF had a 22% relative risk reduction for all cardiac events and a 31% reduced risk for fatal cardiac events compared to those on c -Abstract Truncated-
oncology,medicine, research & experimental